Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.
1 report, 1 independent
Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
-
Nasdaq
American fully electronic stock exchange
Related events
- Stock trading activity for multiple companies, including Ultragenyx, Casey’s General Stores, Plains All American Pipeline, Weyerhaeuser, Zymeworks, and Ciena, was reported on the Nasdaq exchange on September 3, 2026.
- Director Jason Haas sold shares of Ligand Pharmaceuticals on September 13, 2026, which traded on the Nasdaq.
- BioCryst Pharmaceuticals traded on the NASDAQ electronic stock exchange on September 12, 2026.
- Palvella Therapeutics, Inc. stock is trading on the Nasdaq exchange, and the NDA review for its product QTORIN is currently underway.
- Trades are taking place on the Nasdaq stock exchange involving HCW Biologics.